Home › Sickle Cell Disease › Connecticut › New Haven
Sickle Cell Disease clinical trials in New Haven, CT
4 studies for Sickle Cell Disease are looking for participants at sites in and around New Haven (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
RecruitingPhase 1/2Healthy volunteers welcome
- Yale-New Haven Hospital, New Haven
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
RecruitingPhase 2/3
- Smilow Cancer Hospital, New Haven
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RecruitingObservational study
- Yale Hemophilia Treatment Center, New Haven
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
RecruitingPhase 1/2
- Yale School of Medicine, New Haven
About Sickle Cell Disease
Sickle cell disease is a group of inherited disorders that affect your red blood cells. It can cause pain, anemia, and other problems. Learn about treatments.
More about Sickle Cell Disease on MedlinePlus
Sickle Cell Disease trials in other cities
- Atlanta, GA22 studies
- Washington, DC20 studies
- Memphis, TN18 studies
- Chicago, IL18 studies
- Philadelphia, PA15 studies
- Birmingham, AL14 studies
- New York City, NY13 studies
- St. Louis, MO12 studies
- Durham, NC10 studies
- Cincinnati, OH10 studies
- Houston, TX10 studies
- Boston, MA10 studies
Other studies in New Haven
- Non-Small Cell Lung Cancer41 studies
- Breast Cancer37 studies
- Cancer (all types)33 studies
- Metastatic Cancer23 studies
- Lung Cancer22 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Ovarian Cancer21 studies
- Colorectal Cancer20 studies
- Prostate Cancer20 studies
- Opioid Overdose18 studies
- Alcohol Use Disorder (AUD)17 studies
- Acute Myeloid Leukemia17 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.